Instructions for Use

For the qualitative measurement of IgM class antibodies against Tick-borne encephalitis (TBE) virus in Human serum and plasma (citrate).

This product is for research use only and is not intended for diagnostic use.
# Table of Contents

**INTRODUCTION**
1. BACKGROUND 2  
2. ASSAY SUMMARY 4

**GENERAL INFORMATION**
3. PRECAUTIONS 5  
4. STORAGE AND STABILITY 5  
5. MATERIALS SUPPLIED 5  
6. MATERIALS REQUIRED, NOT SUPPLIED 6  
7. LIMITATIONS 6  
8. TECHNICAL HINTS 7

**ASSAY PREPARATION**
9. REAGENT PREPARATION 8  
10. SAMPLE COLLECTION AND STORAGE 8  
11. SAMPLE PREPARATION 8  
12. PLATE PREPARATION 9

**ASSAY PROCEDURE**
13. ASSAY PROCEDURE 10

**DATA ANALYSIS**
14. CALCULATIONS 12  
15. TYPICAL SAMPLE VALUES 15  
16. ASSAY ANALYTICAL SPECS 15

**RESOURCES**
17. INTERFERENCES 16  
18. TROUBLESHOOTING 16  
19. NOTES 18
1. BACKGROUND

Abcam’s anti-Tick-borne encephalitis (TBE) virus IgM Human in vitro ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the accurate qualitative measurement of IgM class antibodies against Tick-borne encephalitis virus in Human serum and plasma.

A 96-well plate has been precoated with Tick-borne encephalitis antigens to bind cognate antibodies. Controls or test samples are added to the wells and incubated. Following washing, a horseradish peroxidase (HRP) labelled anti-Human IgM conjugate is added to the wells, which binds to the immobilized Tick-borne encephalitis-specific antibodies. TMB is then catalyzed by the HRP to produce a blue color product that changes to yellow after adding an acidic stop solution. The density of yellow coloration is directly proportional to the amount of Tick-borne encephalitis IgM sample captured in plate.

Tick-borne encephalitis (TBE) virus is a flavivirus. It is an enveloped single-stranded RNA virus with cubic icosahedral symmetry and ranges in size from 20-80nm in diameter.

On the European continent only two antigenic subtypes exist which show only little differences in their structural proteins.

TBE virus is mainly transmitted by ticks. The degree of contamination of ticks (and thus Humans) in central Europe increases from west to east, and anybody may be affected. Specific antibody development yields a life-long immunity.

TBE is the most important tick-transmitted disease of man -beside Lyme disease, which is caused by the spirochete Borrelia burgdorferi. The clinical course of the disease depends on the immune status of the infected person. A high virus production in the primary infected tissues is required to pass the blood-brain barrier, resulting in severe manifestations in the central nervous system.
<table>
<thead>
<tr>
<th>Species</th>
<th>Disease</th>
<th>Symptoms</th>
<th>Mechanism of Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>TBE Virus</td>
<td>Tick-borne encephalitis</td>
<td>Mild, influenza-type illness; fever, severe headache and neck rigidity with transient paralysis of the limbs, shoulders or, less commonly, the respiratory musculature; nausea</td>
<td>Transmission mainly by tick bites (Ixodes ricinus, western subtype; Ixodes persulcatus, eastern subtype), but also through ingestion of infected (non-pasteurized) milk.</td>
</tr>
<tr>
<td></td>
<td>CEE (Central European Encephalitis)</td>
<td></td>
<td>No transmission from one person to another</td>
</tr>
<tr>
<td></td>
<td>RSSE (Russian Spring Summer Encephalitis)</td>
<td></td>
<td>Incubation period: 7-14 days</td>
</tr>
</tbody>
</table>

Of the two subtypes, RSSE causes the more severe infection, having an incidence of mortality of up to 25% in some outbreaks, whereas mortality in CEE seldom exceeds 5%. An inactivated TBE virus vaccine is available in Europe and Russia. The presence of infection may be identified by:

- Haemagglutination-Inhibition, Complement Fixation
- Detection of specific antibodies by CIE, ELISA
2. **ASSAY SUMMARY**

Prepare all reagents, samples and controls as instructed.

Add samples and controls to wells used. Incubate at 37°C.

Wash each well and add prepared labeled HRP-Conjugate. Incubate at room temperature.

After washing, add TMB substrate solution to each well. Incubate at room temperature. Add Stop Solution to each well. Read immediately.
3. PRECAUTIONS
Please read these instructions carefully prior to beginning the assay.
All kit components have been formulated and quality control tested to function successfully as a kit. Modifications to the kit components or procedures may result in loss of performance.

4. STORAGE AND STABILITY
Store kit at 2-8°C immediately upon receipt.
Refer to list of materials supplied for storage conditions of individual components. Observe the storage conditions for individual prepared components in section 9. Reagent Preparation.

5. MATERIALS SUPPLIED

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
<th>Storage Condition (Before Preparation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tick-borne encephalitis (IgM) Coated Microplate (12 x 8 wells)</td>
<td>96 Wells</td>
<td>2-8°C</td>
</tr>
<tr>
<td>IgM Sample Diluent***</td>
<td>100 mL</td>
<td>2-8°C</td>
</tr>
<tr>
<td>Stop Solution</td>
<td>15 mL</td>
<td>2-8°C</td>
</tr>
<tr>
<td>20X Washing Solution*</td>
<td>50 mL</td>
<td>2-8°C</td>
</tr>
<tr>
<td>Tick-borne encephalitis virus anti-IgM HRP Conjugate**</td>
<td>20 mL</td>
<td>2-8°C</td>
</tr>
<tr>
<td>TMB Substrate Solution</td>
<td>15 mL</td>
<td>2-8°C</td>
</tr>
<tr>
<td>Tick-borne encephalitis virus IgM Positive Control***</td>
<td>2 mL</td>
<td>2-8°C</td>
</tr>
<tr>
<td>Tick-borne encephalitis virus IgM Cut-off Control***</td>
<td>3 mL</td>
<td>2-8°C</td>
</tr>
<tr>
<td>Tick-borne encephalitis virus IgM Negative Control***</td>
<td>2 mL</td>
<td>2-8°C</td>
</tr>
</tbody>
</table>

* Contains 0.1 % Bronidox L after dilution
** Contains 0.2 % Bronidox L
*** Contains 0.1 % Kathon
6. **MATERIALS REQUIRED, NOT SUPPLIED**

These materials are not included in the kit, but will be required to successfully utilize this assay:

- Microplate reader capable of measuring absorbance at 450 nm or 620 nm
- Incubator at 37°C
- Multi and single channel pipettes to deliver volumes between 10 and 1,000 µL
- Optional: Automatic plate washer for rinsing wells
- Vortex tube mixer
- Deionised or (freshly) distilled water
- Disposable tubes
- Timer

7. **LIMITATIONS**

- ELISA kit intended for research use only. Not for use in diagnostic procedures
- All components of Human origin used for the production of these reagents have been tested for anti-HIV antibodies, anti-HCV antibodies and HBsAg and have been found to be non-reactive. Nevertheless, all materials should still be regarded and handled as potentially infectious
- Use only clean pipette tips, dispensers, and lab ware.
- Do not interchange screw caps of reagent vials to avoid cross-contamination
- Close reagent vials tightly immediately after use to avoid evaporation and microbial contamination
- After first opening and subsequent storage check conjugate and control vials for microbial contamination prior to further use
• To avoid cross-contamination and falsely elevated results pipette patient samples and dispense conjugate, without splashing, **accurately** to the bottom of wells

8. **TECHNICAL HINTS**

• Avoid foaming or bubbles when mixing or reconstituting components

• Avoid cross contamination of samples or reagents by changing tips between sample, standard and reagent additions.

• Ensure plates are properly sealed or covered during incubation steps

• Complete removal of all solutions and buffers during wash steps is necessary for accurate measurement readings

• This kit is sold based on number of tests. A ‘test’ simply refers to a single assay well. The number of wells that contain sample, control or standard will vary by product. Review the protocol completely to confirm this kit meets your requirements. Please contact our Technical Support staff with any questions
9. **REAGENT PREPARATION**

Equilibrate all reagents, samples and controls to room temperature (18-25°C) prior to use.

9.1 **1X Washing Solution**

Prepare 1X Washing Solution by diluting 20X Washing Solution with deionized water. To make 200 mL 1X Washing Solution combine 10 mL 20X Washing Solution with 190 mL deionized water. Mix thoroughly and gently.

- All other solutions are supplied ready to use

10. **SAMPLE COLLECTION AND STORAGE**

- Use Human serum or plasma (citrate) samples with this assay. If the assay is performed within 5 days of sample collection, the specimen should be kept at 2-8°C; otherwise it should be aliquoted and stored deep-frozen (-20 to -80°C). If samples are stored frozen, mix thawed samples well before testing.

  *Avoid repeated freezing and thawing.*

  Heat inactivation of samples is not recommended

11. **SAMPLE PREPARATION**

- Before assaying, all samples should be diluted 1:100 with IgM Sample Diluent. Add 10 µL sample to 1 mL IgM Sample Diluent to obtain a 1:100 dilution. Mix gently and thoroughly.
12. PLATE PREPARATION

- The 96 well plate strips included with this kit are supplied ready to use. It is not necessary to rinse the plate prior to adding reagents.
- Unused well strips should be returned to the plate packet and stored at 4°C.
- For each assay performed, a minimum of 1 well must be used as a blank, omitting sample and conjugate from well addition.
- For statistical reasons, we recommend each standard and sample should be assayed with a minimum of two replicates (duplicates).
13. ASSAY PROCEDURE

- Equilibrate all materials and prepared reagents to room temperature prior to use.

- Please read the test protocol carefully before performing the assay. Reliability of results depends on strict adherence to the test protocol as described.

- If performing the test on ELISA automatic systems we recommend increasing the washing steps from three to five and the volume of washing solution from 300 µL to 350 µL to avoid washing effects.

- All controls (Tick-borne encephalitis IgM Positive, Tick-borne encephalitis IgM Negative and Tick-borne encephalitis IgM Cut-off) must be included with each assay performed to determine test results.

- Assay all standards, controls and samples in duplicate.

  13.1. Prepare all reagents, standards, and samples as directed in the previous sections.

  13.2. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, reseal and return to 4°C storage.

  13.3. Add 100 µL of controls and diluted sample into appropriate wells. Leave one well for substrate blank.

  13.4. Cover wells with the foil supplied in the kit and incubate for 1 hour at 37°C.

  13.5. Remove the foil, aspirate the contents of the wells and wash each well three times with 300 µL of 1X Washing Solution. Avoid spill over into neighboring wells. The soak time between each wash cycle should be >5 sec. After the last wash, remove the remaining 1X Washing Solution by aspiration or decanting. Invert the plate and blot it against clean paper towels to remove excess liquid.

  Note: Complete removal of liquid at each step is essential for good assay performance.
13.6. Add 100 µL Tick-borne encephalitis virus anti-IgM HRP Conjugate into all wells except for the blank well. Cover with foil.

13.7. Incubate for 30 minutes at room temperature. Do not expose to direct sunlight.

13.8. Repeat step 13.5.

13.9. Add 100 µL TMB Substrate Solution into all wells

13.10. Incubate for exactly 15 minutes at room temperature in the dark.

13.11. Add 100 µL Stop Solution into all wells in the same order and at the same rate as for the TMB Substrate Solution.
   
   Note: Any blue color developed during the incubation turns into yellow.

13.12. Highly positive samples can cause dark precipitates of the chromogen. These precipitates have an influence when reading the optical density. Predilution of the sample with PBS for example 1:1 is recommended. Then dilute the sample 1:100 with IgM Sample Diluent and multiply the results in Standard Units by 2 (See Section 14. Calculations.)

13.13. Measure the absorbance of the specimen at 450 nm within 30 minutes of addition of the Stop Solution.

   *Dual wavelength reading using 620 nm as reference wavelength is recommended.*
14. **CALCULATIONS**

In order for an assay to be considered valid, the following criteria must be met:

- **Substrate blank:** Absorbance value < 0.100
- **Negative control:** Absorbance value < 0.200 and < cut-off
- **Cut-off control:** Absorbance value 0.150 – 1.300
- **Positive control:** Absorbance value > cut-off

If these criteria are not met, the test is not valid and must be repeated.

**Calculation of Results**

Calculate the mean background subtracted absorbances for each sample and compare to mean Cut-off control value.

The Cut-off control value is the mean absorbance value of the Cut-off control wells.

*Example:* Absorbance value Cut-off control Well 1 = 0.156  
Absorbance value Cut-off control Well 2 = 0.168

Mean Cut Off value: \((0.156 + 0.168)/2 = 0.162\)

**Interpretation of Results**

Samples are considered to give a positive signal if the absorbance value is greater than 10% over the cut-off value.

Samples with an absorbance value of less than 10% above or below the Cut-off control value should be considered as inconclusive (grey zone) i.e. neither positive or negative. It is recommended to repeat the assay using fresh samples. If results of the second test are again less than 10% above or below the Cut-off control value the sample has to be considered negative.

Samples are considered negative if the absorbance value is lower than 10% below the cut-off.
Results in Standard Units

Patient (mean) absorbance value $\times 10$ = Standard Units

Cut-off

Example: \[ \frac{1.786 \times 10}{0.38} = 47 \text{ Standard Units} \]

Cut-off: 10 Standard Units
Grey zone: 9-11 Standard Units
Negative: <9 Standard Units
Positive: >11 Standard Units
## Results after vaccination

<table>
<thead>
<tr>
<th>TBE IgG</th>
<th>TBE IgM</th>
<th>Status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td></td>
<td></td>
<td>No seroconversion after vaccination. This may be the case after the first vaccination during basic immunisation. Patients who show low or no response.</td>
</tr>
<tr>
<td>Grey zone</td>
<td></td>
<td></td>
<td>This may be a case of seroconversion. Continue with basic immunisation or booster. Repeat test within 2-4 weeks. A non-specific reaction is not excluded.</td>
</tr>
<tr>
<td>Positive</td>
<td></td>
<td></td>
<td>This is a case of seroconversion. Check anamnestic data and if necessary complete basic immunization or give a booster.</td>
</tr>
</tbody>
</table>

## Results after TBE infection

<table>
<thead>
<tr>
<th>TBE IgG/IgM</th>
<th>TBE IgG</th>
<th>TBE IgM</th>
<th>Status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td></td>
<td></td>
<td></td>
<td>No infection with the TBE Virus</td>
</tr>
<tr>
<td>Positive</td>
<td></td>
<td>Negative</td>
<td></td>
<td>Latent immunisation or the infection occurred weeks or months before</td>
</tr>
<tr>
<td>Negative</td>
<td></td>
<td>Positive</td>
<td></td>
<td>A TBE Virus infection is possible. In the early phase the TBE IgG can be negative or grey zone. Repeat test within 7-10 days to monitor the levels of the antibodies. It is recommended to verify this result with another test system.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td></td>
<td></td>
<td></td>
<td>A TBE Virus infection is most probable if no vaccination was performed. It is recommended to verify this result with another test system.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grey zone</td>
<td></td>
<td></td>
<td></td>
<td>A new blood specimen has to be tested within 7-10 days to monitor the antibody levels.</td>
</tr>
</tbody>
</table>
15. TYPICAL SAMPLE VALUES

PRECISION –

<table>
<thead>
<tr>
<th>TBE Virus</th>
<th>Intra-Assay</th>
<th>Inter-Assay</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=</td>
<td>12</td>
<td>24</td>
</tr>
<tr>
<td>Mean</td>
<td>0.72</td>
<td>0.73</td>
</tr>
<tr>
<td>%CV</td>
<td>7.5</td>
<td>8.9</td>
</tr>
</tbody>
</table>

16. ASSAY ANALYTICAL SPECS

SPECIFICITY -

The specificity is 95 % and is defined as the probability of the assay scoring negative in the absence of the specific analyte.

SENSITIVITY -

The sensitivity is 80 % and is defined as the probability of the assay scoring positive in the presence of the specific analyte.
17. INTERFERENCES
Interferences with hemolytic, lipemic or icteric sera are not observed up to a concentration of 10 mg/mL hemoglobin, 5 mg/mL triglycerides and 0.2 mg/mL bilirubin.

18. TROUBLESHOOTING

<table>
<thead>
<tr>
<th>Problem</th>
<th>Cause</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incubation time to short</td>
<td>Precipitate can form in wells upon substrate addition when concentration of target is too high</td>
<td>Try overnight incubation at 4 °C</td>
</tr>
<tr>
<td>Low signal</td>
<td>Using incompatible sample type (e.g. serum vs. cell extract)</td>
<td>Increase dilution factor of sample</td>
</tr>
<tr>
<td></td>
<td>Sample prepared incorrectly</td>
<td>Detection may be reduced or absent in untested sample types</td>
</tr>
<tr>
<td></td>
<td>Bubbles in wells</td>
<td>Ensure no bubbles present prior to reading plate</td>
</tr>
<tr>
<td></td>
<td>All wells not washed equally/thoroughly</td>
<td>Check that all ports of plate washer are unobstructed/wash wells as recommended</td>
</tr>
<tr>
<td></td>
<td>Incomplete reagent mixing</td>
<td>Ensure all reagents/master mixes are mixed thoroughly</td>
</tr>
<tr>
<td>Large CV</td>
<td>Inconsistent pipetting</td>
<td>Use calibrated pipettes &amp; ensure accurate pipetting</td>
</tr>
<tr>
<td></td>
<td>Inconsistent sample preparation or storage</td>
<td>Ensure consistent sample preparation and optimal sample storage conditions (e.g. minimize freeze/thaws cycles)</td>
</tr>
<tr>
<td>Problem</td>
<td>Cause</td>
<td>Solution</td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------------------------------</td>
<td>------------------------------------------------------------</td>
</tr>
<tr>
<td>High background</td>
<td>Wells are insufficiently washed</td>
<td>Wash wells as per protocol recommendations</td>
</tr>
<tr>
<td></td>
<td>Contaminated wash buffer</td>
<td>Make fresh wash buffer</td>
</tr>
<tr>
<td></td>
<td>Waiting too long to read plate after adding stop solution</td>
<td>Read plate immediately after adding stop solution</td>
</tr>
<tr>
<td>Low sensitivity</td>
<td>Improper storage of ELISA kit</td>
<td>Store all reagents as recommended. Please note all reagents may not have identical storage requirements.</td>
</tr>
<tr>
<td></td>
<td>Using incompatible sample type (e.g. Serum vs. cell extract)</td>
<td>Detection may be reduced or absent in untested sample types</td>
</tr>
</tbody>
</table>